Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
$21.46
-$0.66(-1.42%)
At close: 4:00 PM EST
$21.46
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$13.70 - $61.07
Previous CloseN/A
Volume30.18K
Average Volume (3M)277.85K
Market Cap
$401.65M
Enterprise ValueN/A
Total Cash (Recent Filing)$268.44M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 19, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding18,716,280
10 Day Avg. Volume201,757
30 Day Avg. Volume277,849
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.78
Price to Sales (P/S)0.00
P/FCF Ratio-6.62
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$81.00Price Target Upside277.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMerck's decision to progress to a Phase 3 study suggests strong data from its Phase 2 CADENCE trial, which could have a positive influence on Tectonic's TX45.
Financial StrengthTectonic ends Q3 with $268.4M on the balance sheet, which is expected to fund operations into the fourth quarter of 2028.
Regulatory ExpectationsMerck's progression in its trial may help to set expectations for a regulatory path to approval for Tectonic's TX45.
Bears Say
Investor SentimentShort interest is at 33.6% of float, indicating significant bearish sentiment among investors.
Trial ChallengesChallenges in the Re-PHIRE trial design could make it difficult to achieve its primary endpoint, influencing TECX negatively.
Trial OutcomesTECX is likely to react negatively if the AZD3427 trial misses its primary endpoint without subgroup or secondary endpoint results.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Tectonic Therapeutic’s market cap is $401.65M.
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is Mar 19, 2026 which is in 65 days.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Nov 06, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.056 by $0.036.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -1.11.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 18,716,280 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.056. Following the earnings report the stock price went up 1.738%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.00 (277.45% Upside)
$81.00 (277.45% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 334.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-51.08%
12-Months-Change
Fundamentals
Return on Equity
-32.21%
Trailing 12-Months
Asset Growth
64.18%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$81.00
▲(277.45% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
38.51% Insiders
13.87% Mutual Funds
28.17% Other Institutional Investors
13.67% Public Companies and Individual Investors
Options Prices
Currently, No data available
---